anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
CNS effects, as evidenced by decreased activity, ataxia, loss of righting reflex, and ptosis were seen in the following animal studies: the 18-month mouse carcinogenicity study at 50 mg/kg/day, the 6-month dog study at 36 mg/kg/day, the 6-month hamster study at 40 mg/kg/day, and in acute, high-dose studies in rats and hamsters (50 mg/kg), rabbits (300 mg/kg) and mice (1500 mg/kg). CNS toxicity in the acute high-dose studies was characterized (in mice) by conspicuous vacuolation in the ventral white columns of the spinal cord at a dose of 5000 mg/kg and (in rats) by edema with separation of myelinated fibers of the ventral spinal tracts and sciatic nerve at a dose of 1500 mg/kg. CNS toxicity, characterized by periaxonal vacuolation, was observed in the medulla of dogs that died after treatment for 5 weeks with 48 mg/kg/day; this finding was not observed in the remaining dogs when the dose level was lowered to 36 mg/kg/day. CNS vascular lesions, characterized by perivascular hemorrhages, edema, and mononuclear cell infiltration of perivascular spaces, have been observed in dogs treated with other members of this drug class. No CNS lesions have been observed after chronic treatment for up to 2 years with fluvastatin in the mouse (at doses up to 350 mg/kg/day), rat (up to 24 mg/kg/day), or dog (up to 16 mg/kg/day). 

Prominent bilateral posterior Y suture lines in the ocular lens were seen in dogs after treatment with 1, 8, and 16 mg/kg/day for 2 years.
Subjects will be monitored using the conventional monitoring strategy for the first 6 months post-ablation. During the next 6 months, subjects will be monitored using the data from the Reveal device, transmitted from home every 30 days.
1312470 Benzofuran and benzothiophene derivatives CIBA GEIGY AG 19 Nov 1970 [20 Nov 1969] 54946/70 Heading C2C Novel compounds of Formula I (in which X is O or S, Y is H or CH 3 , Z 1  is CH 3 , CH 3 O, Cl or F, Z 2  is H or CH 3  and R is C 1-5  alkyl) and their salts with bases, are prepared by (a) reacting a compound of Formula II (in which Z 3  is an oxygen atom or an alkyl-, aryl- or aralkyl-imino group) with a nitroalkane of formula RCH 2 NO 2 , or (b) hydrolysing a corresponding ester of an acid of Formula I. The resulting acids and salts may be interconverted. Compounds of Formula II (in which Z 3  is an oxygen atom) are prepared by reacting a compound of Formula III with a dichloromethyl alkyl ether in the presence of a Friedel-Crafts catalyst in an inert solvent. Esters of acids of Formula I are prepared by reacting a compound of Formula II (in which Z 3  is an oxygen atom) with an alcohol, e.g. ethanol, to form the corresponding carboxylic acid ester, reacting this with an appropriate primary amine to give an ester of a compound of Formula II (in which Z 3  is an alkyl-, aryl- or aralkyl-imino group) and reacting this compound with a nitroalkane of formula RCH 2 NO 2 . 2,3 - Dihydro - 6,7 - dimethylfuran - 2 - carboxylic acid is prepared by reacting 2,3-dimethylphenol with malic acid to form 7,8-dimethylcoumarin, reacting this with bromine in chloroform to form 6,7-dimethylbenzofuran-2-carboxylic acid, and reducing this with sodium amalgam. 2,3 - Dihydro - 6 - chlorobenzothiophene - 2- carboxylic acid is prepared by reacting rhodanine with 2,4-dichlorobenzaldehyde to form 5-(2,4- dichlorobenzylidene)-rhodanine, hydrolysing this to form 2,4-dichloro-α-mercapto-cinnamic acid, cyclizing this by treatment with sodium methylate to form 6-chlorobenzothiophene-2-carboxylic acid and reducing this with sodium amalgam. Pharmaceutical compositions having diuretic and saluretic activity comprise a compound of Formula I, or a pharmaceutically acceptable salt thereof with a base, together with a pharmaceutical carrier. The compositions may be administered orally.
The 4-week MVPA intervention engaged in supervised aerobic exercise, resistance training and interesting sport for 60 minutes, 3 days/week (Monday, Wednesday and Friday). As shown in Table S1, participants completed four sessions including preparation module (15 min), training module (30 min), and relaxation module (15 min). Another aerobic module (15 min) was added in each Friday. Children in intervention group were also encouraged to take exercise for 10 minutes together with their parents at home two hours later after dinner including ten minutes' walking (at least 1000 meters) or at least 200 times rope skipping.
Preeclampsia (PE) is a hypertensive disorder of pregnancy and a major cause of maternal/perinatal adverse health outcomes with no effective therapeutic strategies. Our group previously identified distinct subclasses of PE, one of which exhibits heightened placental inflammation (inflammation-driven PE). In non-pregnant populations, chronic inflammation is associated with decreased levels of cellular NAD+, a vitamin B3 derivative involved in energy metabolism and mitochondrial function. Interestingly, specifically in placentas from women with inflammation-driven PE, we observed the increased activity of NAD+-consuming enzymes, decreased NAD+ content, decreased expression of mitochondrial proteins, and increased oxidative damage. HTR8 human trophoblasts likewise demonstrated increased NAD+-dependent ADP-ribosyltransferase (ART) activity, coupled with decreased mitochondrial respiration rates and invasive function under inflammatory conditions. Such adverse effects were attenuated by boosting cellular NAD+ levels with nicotinamide riboside (NR). Finally, in an LPS-induced rat model of inflammation-driven PE, NR administration (200 mg/kg/day) from gestational days 1-19 prevented maternal hypertension and fetal/placental growth restriction, improved placental mitochondrial function, and reduced inflammation and oxidative stress. This study demonstrates the critical role of NAD+ in maintaining placental function and identifies NAD+ boosting as a promising preventative strategy for PE.
Bisphenol A (BPA) engenders testicular toxicity via hydroxyl free radical genesis in rat striatum and depletion of the endogenous antioxidants in the epididymal sperms. The multi-drug resistance efflux carrier; P-glycoprotein (P-gp) expel the BPA from the testis and is responsible for the testicular protection through the deactivation of numerous xenobiotics. In our study, we investigated whether the BPA-induced testicular toxicity could be circumvented through administration of an antioxidant; crocin (Cr). Implication of P-gp expression was also investigated. Rats administered BPA (10 mg/kg b.w. orally for 14 days), dropped the body weight, testes/body weight ratio, total protein content, testosterone, follicle stimulating hormone, luteinizing hormone, and sperm motility & count, total antioxidant status, glutathione content and antioxidant enzymes (superoxide dismutase and catalase), concomitant with the elevation of the percentage abnormal sperm morphology, as well as testicular lipid peroxides and nitrite/nitrate levels. Histopathological examination showed spermatogenesis disorders after the BPA rats exposure. The immunohistochemical study showed up-regulation of the P-gp as evident by increasing immunoreactivity in interstitial cells, with positive localization in some spermatogonia cells. The BPA-treated rats showed positive immunoreactivity against caspase-3. The co-intake of Cr (200 mg/kg b.w./day, i.p. 14 days) along with the BPA, significantly ameliorated all the mentioned parameters, boosted histopathological image, fell the caspase-3 up-regulation, and perched the P-gp expression. We showed that, Cr promotes P-gp as an approach to nurture the testicles against the BPA toxicity. In conclusion; Cr lessens the oxidative stress conditions to safeguard rats from the BPA-induced testicular toxicity and sex hormones abnormalities, reducing apoptosis and up-regulating P-gp.
The volunteers will be healthy men and women aged 18 to 65 with a BMI between 18.5 and 30 kg/m2. Volunteers will provide a single stool sample to compare 16S rRNA gene sequencing results for gut microbiota between faeces processed from standard stool sample and those collected by the collection device (EXTEL HEMO AUTO MC Collection Picker) used in the Scottish Bowel Screening Programme.
The de-identification system can be operable to receive, from at least one first entity, a medical scan and a corresponding medical report. A set of patient identifiers can be identified in a subset of fields of a header of the medical scan. A de-identified medical scan can be generated by replacing the subset of fields of the header of the medical scan with a corresponding set of anonymized fields generated by performing a header anonymization function. A subset of patient identifiers of the set of patient identifiers can be identified in the medical report. A de-identified medical report can be generated by replacing each of the subset of patient identifiers with corresponding anonymized placeholder text generated by performing a text anonymization function on the subset of patient identifiers. The de-identified medical scan and the de-identified medical report can be transmitted to a second entity via a network.
There are a number of medical assessment tools for various diseases, but in most cases such tools are designed to reflect the perspective of healthcare providers, not perspective of patients. In addition to clinical results, it is necessary to evaluate the quality of life of patients when measuring the effect of medical treatments. Thus, evaluation criteria which can be useful as patient-reported outcome indices, have received increasing attention in recent years. Health-related quality of life provides a patient-reported assessment. Japanese Orthopaedic Association Hip Disease Evaluation Questionnaire (JOAHDEQ) evaluates quality of life related to hip disorders. It is also a guide in determining the expectations of individuals in the treatment process. It consists of 3 subscales (pain, movement and mental) and 20 items. Hip condition and pain are evaluated with a 100 mm scale. 20 items are scaled likert with values between 0 and 4. "0" means "strongly agree", "1" means "agree", "2" means "uncertain", "3" means "disagree" and "4" means "strongly disagree". The study is planned with 105 individuals with hip disease. After questioning the sociodemographic characteristics of the individuals, the patients will be asked to fill in JOAHDEQ, Oxford Hip Score, International Hip Outcome Tool-12, Short Form-36, and Visual Analog Scale Test-retest will be re-applied to those of the same individuals who can be reached after 1 week. The results will be analyzed using the SPSS version 22.0 computer package program.
Seventeen monoclonal antibodies derived from fusions with spleen cells of mice immunized with established culture lines of renal cancers identified nine cell surface antigenic systems. Six of the systems (gp 160, S 25 , gp120r, gp120nr, gp115, and V,) represents antigens not previously described. The most restricted of the newly described antigens are gp160, S 25 , and gp1120r. These determinants are found only on cells or renal origin, both normal and malignant, and represent differentiation antigens of human kidney. These systems can be used to characterize and study the nature of renal cancer. Thus, comparison of the S 25  and the gp160 phenotypes of different renal cancer cell lines and cultures of normal kidney clearly distinguish these two systems.
The maximum recommended intrathecal PRIALT dose is 19.2 mcg/day. The maximum intrathecal dose of PRIALT in clinical trials was 912 mcg/day. In some patients who received intrathecal doses greater than the maximum recommended dose, exaggerated pharmacological effects (e.g., ataxia, nystagmus, dizziness, stupor, unresponsiveness, spinal myoclonus, confusion, sedation, hypotension, word-finding difficulties, garbled speech, nausea, and vomiting) were observed. There was no indication of respiratory depression. Overdoses may occur due to pump programming errors or incorrect drug concentration preparations. In these cases, patients were observed and ziconotide was either temporarily discontinued or permanently withdrawn. Most patients recovered within 24 hours after withdrawal of drug. In the event of an overdose, elimination of ziconotide from CSF would be expected to remain constant (CSF t½=4.6 hours). Therefore, within 24 hours of stopping therapy, the ziconotide CSF concentration should be less than 5% of peak levels. 

There is no known antidote to ziconotide. General medical supportive measures should be administered to patients who receive an overdose until the exaggerated pharmacological effects of the drug have resolved. Treatment for an overdose is hospitalization, when needed, and symptom-related supportive care. Ziconotide does not bind to opiate receptors and its pharmacological effects are not blocked by opioid antagonists. 

In the event of an inadvertent intravenous or epidural administration, adverse reactions could include severe hypotension, which can be treated with a recumbent posture and blood pressure support as required. The half-life of PRIALT in serum is 1.3 hours.
The overall nature of this study is to conduct an investigation into the metabolic effects of acute high fructose versus high glucose feeding in people of Black African (BA) compared to age and BMI-matched control subjects of White-European (WE) origin . The research question of our study is: do people of BA metabolise fructose differently than people of WE when challenged with a high sugar diet? Therefore, our specific aims are to determine the following in both people of BA and WE consuming both high fructose and high glucose meals: 1) the postprandial pattern of blood insulin, glucose, triglyceride and cholesterol concentrations; 2) ambulatory blood pressure measures during the postprandial period and 4) postprandial and 0-24-hour fasted serum and red blood cell membrane cholesterol and non-cholesterol sterol concentrations.

Potential participants will attend the scheduled screening session where the requirements of participation will be described and the participants will be given an opportunity to ask any questions they may have. Those still willing to participate will sign the informed consent form before the screening assessment is performed. Screening will require a fasted blood sample to be taken as well as a brief questionnaire to ascertain ethnicity (self-declared), medications and health status. An assessment of weight, height and waist circumference will also be taken to confirm they meet the inclusion criteria. It is expected that the results of the screening blood sample will be available within 1-2 weeks. Those participants meeting the inclusion criteria will be contacted and scheduled for the first study visit. Those not meeting the criteria will be notified by their preferred means of contact, a copy of their results will be provided.

Prior to attending participants treatment order will be randomized. Participants will report to the Metabolic Research Unit (MRU) at 08.00 following an overnight fast. A catheter will be inserted into an antecubital vein for collection of blood samples and a baseline blood sample collected at this time. Participant will be asked to undertake minimal physical activity during the remainder of the study period. A breakfast meal will be given at 0min, the lunch meal at 240min and meals will be consumed within 15 minutes. Participants will be fitted with a portable continuous blood pressure and heart rate monitor (arteriograph) and instructed on what to expect as it functions. Further blood samples will be taken at -30, -15, 0, 15, 30, 45, 60, 90, 120, 180, 240, 300, 360, 420min and at 24hrs (1440min, fasted). The energy content of the meals will be the estimated energy requirements of the participant (to the nearest 100kcals), with 20% of total daily energy coming from glucose or fructose. The glucose or fructose will be given dissolved water with added colour and orange/fruit flavours and provided at breakfast, lunch and supper. The remaining daily caloric requirement for each participant will be given a standardized evening meal to take away and consume at home.
Advances in the clinical management of pediatric B-cell acute lymphoblastic leukemia (B-ALL) have dramatically improved outcomes for this disease. However, relapsed and high-risk disease still contribute to significant numbers of treatment failures. Development of new, broad range therapies is urgently needed for these cases. We previously reported the susceptibility of ETV6-RUNX1+ pediatric B-ALL to inhibition of signal transducer and activator of transcription 3 (STAT3) activity. In the present study, we demonstrate that pharmacological or genetic inhibition of STAT3 results in p53 induction and that CRISPR-mediated TP53 knockout substantially reverses susceptibility to STAT3 inhibition. Furthermore, we demonstrate that sensitivity to STAT3 inhibition in patient-derived xenograft (PDX) B-ALL samples is not restricted to any particular disease subtype, but rather depends on TP53 status, the only resistant samples being TP53 mutant. Induction of p53 following STAT3 inhibition is not directly dependent on MDM2 but correlates with degradation of MDM4. As such, STAT3 inhibition exhibits synergistic in vitro and in vivo anti-leukemia activity when combined with MDM2 inhibition. Taken together with the relatively low frequency of TP53 mutations in this disease, these data support the future development of combined STAT3/ MDM2 inhibition in the therapy of refractory and relapsed pediatric B-ALL.
Eligible, consented participants who are unable to attend the weekly exercise sessions will serve as a cohort control group. Participants will be asked to complete patient reported measures of anxiety, depression, and exercise behaviour within 3 days of biopsy, and 6 weeks post biopsy.
Diabetic ketoacidosis accounts for 65% of hospitalizations in pediatric patients with type 1 diabetes, and has a mortality rate between 0.15-0.31%. Children with established type 1 diabetes have an 8% annualized risk of developing diabetic ketoacidosis, and this risk increases during adolescence. In addition, socioeconomic and racial disparities are associated with increased risks of poor glycemic control, hospitalization with diabetic ketoacidosis, and even severe hypoglycemia. All of these complications are associated with preventable harm, and lead to increased utilization of medical resources, both in the short- and long-term. Social determinants of health account for over 75% of health outcomes. Thus, it is not surprising that a disproportionate number of children with poor diabetes control and recurrent hospitalization in diabetic ketoacidosis come from vulnerable underserved populations.

In this study, Investigators will study the effect of integrating a community-based healthcare worker into the healthcare team of children with poorly controlled type 1 diabetes. Community Health Workers (CHW) are highly motivated, community members who do not necessarily have prior medical training, but rather they link with the healthcare team to identify and provide relevant social supports to the family. They receive specific training that focuses on issues relevant to improving health outcomes and adherence, by improving medication access, reducing food insecurity, and improving health literacy. The CHW are able to provide real-time assistance with navigating the healthcare and social services systems, reducing family stress and breaking down community barriers to positive health behavior. The CHW work with the family to develop goals and develop an individualized plan to reach these goals. The role of the CHW can include home visits, phone contacts, meeting with school representatives and accompanying patients to appointments.

At the diabetes center at The Children's Hospital of Philadelphia (CHOP), the Community Health Worker will be assigned for one year to patients with high healthcare utilization and / or poorly controlled type 1 diabetes. The support provided for this year will be tailored to the patient's needs but may include problem solving surrounding issues related to work/education, accessing healthcare/medications, engagement with the healthcare team, transportation, housing or food insecurity. Interactions with patients will be through home visits, telephone encounters, text messaging or email. This will be added to their medical care and will be documented in the patient's medical record.
The almond intervention will be roasted almonds 56 grams/day for 28 days. The caloric value is approximately 350 kcals.
Absorption/Elimination   
In an animal study (pigs, n =38), after a single dose of 40 mg of labeled prussian blue insoluble, 99% of the administered prussian blue dose was excreted unchanged in feces. Absorption from multiple doses has not been studied. 

In a study using rats (n = 40, mean body weight range of 188 – 219 grams) injected with 137Cs, a dose response relationship was demonstrated for the amount of radiation elimination with prussian blue insoluble at doses of 1 to 50 mg/day (Table 1). There is little difference in radiation elimination rate between prussian blue insoluble at doses of 50 to 100 mg/day. In Table 1, the % of Injected Radiation Dose Remaining is defined as the percentage of the total injected dose of 137Cs remaining in the body at 96 hours post administration. 

In studies of rats, pigs, and dogs that were internally contaminated with cesium and thallium, the presence of the insoluble complexes in the gastrointestinal lumen changed the primary elimination route from the kidney to the feces and increased the rate of elimination of these two contaminants.
The invention relates to the use of cyclodextrin complexes containing lipoic acid, said complexes consisting of at least one representative of the series of unsubstituted alpha-cyclodextrin, beta-cyclodextrin and gamma-cyclodextrin, and at least one representative of the series of racemic alpha-lipoic acid, racemic dihydrolipoic acid and the derivatives thereof, for producing a food supplement, a functional food supplement, a clinical nutrition product and/or a cosmetic preparation in the non-medical field of application. Said complex, which contains at least 20 wt. % of the cyclodextrin component, preferably in food quality, can also contain water and reaction products or secondary reaction products from the complex production, especially alpha-cyclodextrin being used. The cyclodextrin/(dihydro)liponic acid complexes can be used, preferably combined with other bioactive components, aromas and/or texturing products, and also the standard formulation auxiliary agents, to produce an agent for preventing and/or treating symptoms of an inflammatory nature and especially arthritis, damage to the liver function and especially alcohol intoxication, paraesthesiae and neuropathies, and for producing agents having cytoprotective and/or antiphlogistic and/or antinociceptive (analgesic) properties and/or properties that counteract the formation of radicals. Said complexes can also preferably be used to produce an agent for stimulating glucose metabolism and/or transport in muscles and/or lipocytes, agents for reinforcing the energy metabolism of the body and the brain, agents for increasing the endurance, capacity, attentiveness, concentration of the memory, agents for the prevention and/or treatment of diabetes Typ2, and agents for caring for at least partially keratinised parts of the body, especially the skin, hair, fingernails and toenails. The invention enables products to be obtained, which can be taken by the end consumer under improved compliance conditions in the non-medical field of indication, due to the distinctive stability of the agents.